FDA Invites Comment on Drug Testing Guidance for Early AD
percent.”—Esther Landhuis Submitted to The New York Times on 18 March 2013 To the Editors, Nearly half of the
373 RESULTS
You searched Landhuis
Sort By:
percent.”—Esther Landhuis Submitted to The New York Times on 18 March 2013 To the Editors, Nearly half of the
predict it will be over.”—Esther Landhuis and Gabrielle Strobel. None
and NMDA receptor antagonists.—Esther Landhuis None http://www.alzforum.org/new/detail.asp?id=1879
in a commentary accompanying the study by Edwards and colleagues (Surmeier, 2010).—Esther Landhuis
strength for the duration of the study,” she said.—Esther Landhuis. This is Part 1 of a two-part series.
skills, language, and memory development.—Esther Landhuis None
buildup.—Esther Landhuis None http://www.alzforum.org/new/detail.asp?id=3244 Alzheimer's Disease Imaging
Landhuis None http://www.alzforum.org/new/detail.asp?id=3348 Alzheimer's Disease Amyloid Clinical
enzyme replacement therapy for Gaucher’s patients.—Esther Landhuis None
in neurons upon NMDA receptor stimulation (Marambaud et al., 2003).—Esther Landhuis None
neuronal loss, will be key to sorting out the role of inflammation in AD.—Esther Landhuis None
February in the journal Biochemistry (Yu et al., 2009).—Esther Landhuis None
option.—Esther Landhuis. This is Part 1 of a two-part series. See Part 2 Q&A With Sue Anderson, FDA
nicotinamide are safe.—Esther Landhuis None http://www.alzforum.org/new/detail.asp?id=1962 Alzheimer's
deficits in vivo.—Esther Landhuis None http://www.alzforum.org/new/detail.asp?id=2358 Alzheimer's